业内知名大型制药公司施贵宝(BMY)今日盘前大跌5.38%,引发市场广泛关注。
消息面上,施贵宝公布了2025年业绩预期,预计全年营收约455亿美元,较市场预期低约19亿美元。公司主要原因是旗下多款重磅老药面临仿制药冲击,销售收入料将大幅下滑。其中包括抗癌重磅药物Revlimid、Pomalyst、Sprycel和Abraxane,预计销售收入将下滑18%至20%。
与此同时,施贵宝还将扩大成本削减计划。该公司宣布,到2027年底,将把成本削减计划再扩大20亿美元,使总削减额达35亿美元。这一系列举措都显示出,该公司正在为应对业绩下滑做出各种自救。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.